Arrien out-licenses RORgammaT series and autoimmune candidate ARN-6039

Arrien Pharmaceuticals LLC (Salt Lake City, Utah) granted an undisclosed pharmaceutical company worldwide rights to ARN-6039 and a series of compounds targeting RAR-related orphan receptor C thymus-specific isoform (RORgamma2; RORgammaT). Arrien said the target is implicated in dermatological and autoimmune diseases, including psoriasis.

ARN-6039, a small molecule inverse agonist of RORgammaT, has completed a Phase I safety trial in healthy volunteers. Arrien expects the partner to begin Phase II testing by year end. Arrien discovered using the compound using its fragment-based discovery platform (FIELDS)...